AbbVie is set to acquire University of Pennsylvania’s spinout, Capstan Therapeutics

📢 AbbVie is set to acquire University of Pennsylvania’s spinout, Capstan Therapeutics for up to $2.1 billion in cash, representing one of the major acquisitions in the CGT space in 2025.

⭐ The acquisition price represents a significant premium over Capstan's last valuation, however, with this deal AbbVie gains full access to Capstan's key programs and most importantly its proprietary in vivo cell engineering technology, which was developed by the world-renowned scientists.

⭐ Moreover, the Capstan’s technology was backed by the venture arms of Big Pharma, including Pfizer, Bayer, Eli Lilly, Bristol Myers Squibb and Novartis.

⭐ Recent high-profile transactions, including AstraZeneca's acquisition of EsoBiotec, demonstrate the market's willingness to assign substantial valuations to promising in vivo platforms.

👇 In the attached slides, we have provided basic details of the deal. For an in-depth analysis of all deals in the cell therapy space, please explore Oncofocus’ CGT Watch.

📧 For further details, please write to us at support@oncofocus.com.

🌐 References:

1) https://news.abbvie.com/2025-06-30-AbbVie-to-Acquire-Capstan-Therapeutics,-Further-Strengthening-Commitment-to-Transforming-Patient-Care-in-Immunology

2) https://www.capstantx.com/science-platform/

3) https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-to-acquire-esobiotec.html